These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15784133)

  • 1. Trends in the prevalence and management of diagnosed type 2 diabetes 1994-2001 in England and Wales.
    Lusignan S; Sismanidis C; Carey IM; DeWilde S; Richards N; Cook DG
    BMC Fam Pract; 2005 Mar; 6(1):13. PubMed ID: 15784133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of anti-diabetic medication use in patients with type 2 diabetes mellitus in England and Wales.
    Datta-Nemdharry P; Thomson A; Beynon J; Donegan K
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):127-135. PubMed ID: 27642000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners].
    Fabian W; Majkowska L; Stefański A; Moleda P
    Przegl Lek; 2005; 62(4):201-5. PubMed ID: 16229234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cohort profile: National Diabetes Audit for England and Wales.
    Holman N; Knighton P; Wild SH; Sattar N; Dew C; Gregg EW; Khunti K; Valabhji J; Young B
    Diabet Med; 2021 Sep; 38(9):e14616. PubMed ID: 34062007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes.
    Chalmers J; Hunter JE; Robertson SJ; Baird J; Martin M; Franks CI; Whately-Smith CR; Mariz S; Campbell IW
    Curr Med Res Opin; 2007 Aug; 23(8):1775-81. PubMed ID: 17712875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
    Bailey CJ; Bagdonas A; Rubes J; McMorn SO; Donaldson J; Biswas N; Stewart MW
    Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
    Aljabri K; Kozak SE; Thompson DM
    Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.
    Cook MN; Girman CJ; Stein PP; Alexander CM
    Diabet Med; 2007 Apr; 24(4):350-8. PubMed ID: 17335466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensification of medical management in type 2 diabetes: A real-world look at primary care practice.
    Zekarias K; Davey C; Seaquist E
    J Diabetes Complications; 2020 Jan; 34(1):107477. PubMed ID: 31711841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
    Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH
    Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes.
    Donnelly LA; Doney AS; Hattersley AT; Morris AD; Pearson ER
    Diabet Med; 2006 Feb; 23(2):128-33. PubMed ID: 16433709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
    Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].
    MMW Fortschr Med; 2003 Dec; 145(50):54. PubMed ID: 14963975
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diabetes control in type 2 diabetic subjects treated in primary health care].
    Fabian W; Majkowska L; Moleda P; Stefański A
    Pol Arch Med Wewn; 2006 Aug; 116(2):760-5. PubMed ID: 17424921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.